Drug Metabolism and Pharmacokinetics

Article	Citations
Corrigendum to “Utility of Göttingen minipigs for the prediction of human pharmacokinetic profiles after intravenous drug administration” [Drug Metabol Pharmacokinet 41 (2021) 100408]	189
Effects of genetic polymorphisms of canine CYP2D15 on in vitro hepatic metabolism and in vivo pharmacokinetics of celecoxib, and the strategy for the accurate prediction of human pharmacokinetics	109
The spectrum of hepatic clearance models, from old to new	63
Monocarboxylate transporter 10: substrate-dependent mode of transport	25
Development of an in vitro metabolism approach of acrylamide covalent drugs for predicting metabolism and disposition in human	24
The mass balance recovery, absorption, metabolism, and excretion of [14C]-orvepitant in healthy male subjects after oral dosing: radiosynthesis of [14c]-orvepitant	22
Beyond non-human primates: Transgenics and PBPK models for predicting the human PK of protein therapeutics	17
Formation of reactive metabolites of benzbromarone in humanized-liver mice	15
Clinical studies on pharmacogenomics and DDIS involving drug transporters	15
Applications of model simulation in pharmacological fields and the problems of theoretical reliability	15
Prediction and validation of fetal exposure to dual BCRP/P-GP drug substrates using the proteomics informed efflux ratio-relative expression factor (ER-REF) approach and PBPK modeling and simulation	14
Development of a new assay system for bladder cancer using interactions between cytochromes P450 and serum	14
Dual kinetics of OATP2B1: Inhibitory potency and pH-dependence of OATP2B1 inhibitors	13
In vitro demonstration of antedrug mechanism of a pharmacokinetic booster to improve CYP3A4 substrates by CYP3A4-mediated metabolism inhibition	12
Lysosomal trapping measurement in multiple cell types using a high content imaging (HCI) system	12
Double Trap Interface: A novel gas interface for high throughput analysis of biomedical samples by AMS	12
Human liver chimeric mouse and trasngenic animals are useful tools for quantitatively predicting clearance and drug-drug interactions in human	11
Pharmacokinetics of ginsenosides and effect of the lactic acid bacteria on pharmacokinetics of ginsenosides in mice and human	11
Strategies for enhancing oral exposure of water-insoluble compounds	10
Gene and Oligonucleotide Delivery	9
Mathematical modeling of affinity design goals for CIS-binding BI-specific antibody-based molecules	9
Physiologically based pharmacokinetic modeling to predict the clinical effect of azole antifungal agents as CYP3A inhibitors on azelnidipine pharmacokinetics	9
Enzyme induction fundamentals, assays, data interpretation and in vivo translation	9
Appreciation to Reviewers	9
Effect of linker-payload design on the PK of ADCS	9

This is no longer just about liver: LC-MS proteomics for organ exposure brain/kidney/gut/skin/placenta	8
Effect of antibiotic-administration period on hepatic bile acid profile and expression of pharmacokinetic-related proteins in mouse liver, kidney, and brain capillaries	8
Pharmacokinetic interaction of caffeine and theophylline in mice	8
In vitro and in vivo interactions between nicotine and the cannabis terpene limonene	8
Carboxylesterase-2 plays a critical role in dabigatran etexilate active metabolite formation	8
Cloning, sequence analysis, and tissue expression of marmoset paraoxonase 1	7
IN VITRO AND IN VIVO SYSTEMS FOR PREDICTING THE ADME OF PROTEIN THERAPEUTICS: ARE WE THERE YET?”	7
Clinical studies on pharmacogenomics and DDIS involving drug transporters	7
Disposition of E-selectin-targeting liposomes in tumor spheroids with a perfusable vascular network	7
Strategies for de-risking n-nitrosamine impurities in APIS	7
Suppression and induction of UGT by rhein and alvocidib in intestinal epithelial cells	7
Use of mathematical modeling to guide out-of-the-box thinking for ADC development	7
Lecture title not available	7
Simple confirmation methods for rare but impaired variants of human flavin-containing monooxygenase 3 (FMO3) found in an updated genome resource databank	6
Exposure to mixed microplastic particles altered the fecal microbiome and its associated predictive functional pathways in mice	6
Micro-physiological system of human lung: The current status and application to drug discovery	6
Effect of pregnancy-related hormones on mRNA expression of hepatic drug transporters and enzymes	6
Development of physiologically-based pharmacokinetic models to predict food effects and co-administration of proton pump inhibitors on the pharmacokinetics of sonidegib and vismodegib	6
Spatial mapping of gemcitabine and its pharmacologically active metabolites in tissues using MALDI mass spectrometry imaging	6
A workflow for oligonucleotide metabolite identification studies	6
Corrigendum to “Establishment of human intestinal organoids derived from commercially available cryopreserved intestinal epithelium and evaluation for pharmacokinetic study” [Drug Metabol Pharmacokine	6
Prediction of pharmacokinetics and pharmacodynamics in human for IRAK4 targeted protein degrader	6
Epicatechin gallate and epigallocatechin gallate are potent inhibitors of human arylacetamide deacetylase	5
Effects of valproate, an HDAC inhibitor, on the expression of folate carriers and folate metabolism-related genes in the placenta of rats	5
Opportunities for microphysiological systems from the view of Japanese industries	5
Impact of donor diversity on phase I and phase II activities in cryopreserved human hepatocytes and human liver microsomes	5
Mechanisms of afatinib-induced intestinal epithelial barrier dysfunction using human mini-gut model	5
In vitro metabolic stability and in vivo phaarmacokinetic behavior of panobinostat in mouse models for the treatment of CNS tumors	5
Use of human liver microsomes to assess flavin-containing monooxygenase (FMO) metabolism in vitro	5
Therapeutic application of sequence-specific binding molecules for novel genome editing tools	5
Plausible drug interaction between cyclophosphamide and voriconazole via inhibition of CYP2B6	5
Intestinal microbiota-mediated biotransformations alter the pharmacokinetics of the major metabolites of azathioprine in rats after oral administration	5
The effect of clofazimine in modulating intracellular concentrations of remdesivir and GS-441524: A potential mechanism of enhancing antiviral effects against SARS-COV-2	5
Interactions of sutezolid and its active metabolite with human transporters	5
Prediction of drug-drug interaction risk of P-glycoprotein substrate in drug discovery	5
Oligonucleotide delivery to antigen presenting cells by using schizophyllan	5
Metabolism of non-steroidal anti-inflammatory drugs (NSAIDs) by Streptomyces griseolus CYP105A1 and its variants	5
Experimental validation of the reliability of dilution method for plasma protein binding assay in human plasma using 12 commercial compounds	5
OCT1 transporter kinetics and long-term modulation studies in 3D cultured primary human hepatocytes	5
Development of fluorescent-labeled trapping reagents based on cysteine to detect soft and hard electrophilic reactive metabolites	5
Insights into drug development with quantitative systems pharmacology: A prospective case study of uncovering hyperkalemia risk in diabetic nephropathy with virtual clinical trials	5
Comparative analysis of microcystin toxicity in 2D and 3D cultured primary human hepatocytes	5
Increasing the therapeutic index of ADCs with payload binding selectivity enhancers	4
Comparison on metabolic fate of dendrobium polysaccharides in gut microbiota fermentation process between healty and diabetic status	4
Promiscuity and quantitative contribution of UGT2B17 in drug and steroid metabolism determined by experimental and computational approaches	4
Assessing complex drug-drug interactions using the truvivotm hepatocyte model	4
A practical approach for measuring acyl glucuronide migration half life	4
Acetaminophen-induced liver injury and the microbiome	4
ADME: 14C-RLY-4008 following oral administration to rats	4
Stereoisomer separation of drugs and biomarkers using supercritical fluid chromatography to support PK/PD studies	4

Jasmone, an essential oil component, is an antagonist of aryl hydrocarbon receptor in liver and intestinal cells	4
Verification of a physiologically based pharmacokinetic model of caffeine that incorporates mechanistic descriptors of absorption	4
Beyond the basics: A deep dive into parameter estimation for advanced PBPK and QSP models	4
Evaluation of OSTΑ/Β transporter activity on the basal membrane of CACO-2 cell monolayers	4
Substrate-dependent characteristics in the transport function of SLC19A3: examination of the aspect of its sensitivity to flavonoids	4
Utility of Göttingen minipigs for the prediction of human pharmacokinetic profiles after intravenous drug administration	4
Unveiling the intracellular journey: GOLGA8N-mediated subcellular trafficking of siRNA drugs and its implications on silencing efficacy	4
Evaluating the impact of glycocalyx on partitioning and distribution of basic drugs	4
Species differences between rats and primates (humans and monkeys) in complex cleavage pathways of DS-8500a characterized by 14C-ADME studies in humans and monkeys after administration of two radiolab	3
Evaluation of a novel, primary human hepatocyte tri-culture model, truvivotm, for its ability to predict metabolic clearance of CYP, UGT, and AO substrates	3
Exploration of bioactivation of a branched-chain ketoacid dehydrogenase kinase (BDK) inhibitor	3
Clinical evaluation of [18F]pitavastatin for quantitative analysis of hepatobiliary transporter activity	3
Understanding CYP3A4 and P-GP mediated drug-drug interactions through PBPK modeling - case example of pralsetinib	3
Drug transporters are implicated in the diffusion of tacrolimus into the T lymphocyte in kidney and liver transplant recipients: Genetic, mRNA, protein expression, and functionality	3
Development of template systems for ligand interactions of CYP3A5 and CYP3A7 and their distinctions from CYP3A4 template	3
The effect of traditional herbal medicine on the permeability of clarithromycin and loxoprofen in CACO-2 cell model	3
【Continuous exposure to therapeutic drugs doxorubicin and vincristine reduces drug efficacy through transcriptional and post-transcriptional regulation of P-glycoprotein in follicular lymphoma】	3
Genetic variants of flavin-containing monooxygenase 3 (FMO3) in Japanese subjects identified by phenotyping for trimethylaminuria and found in a database of genome resources	3
The practical impact of the FDA draft guidance on human mass balance studies – a year of client discussions	3
Preclinical evaluation of the potential for cytochrome P450 inhibition and induction by tucatinib	3
Synthetic mRNA for ex vivo therapeutic applications	3
What is the role of CYP1A1 in drug metabolism?	3
Functional assessment of immortalized human brain microvascular endothelial cells with different passage numbers: A case study for a prospective proposal on variability management of in vitro blood-br	3
Adenovirus vector-based vaccine for infectious diseases	2
ADME considerations from FIH to drug approval	2
CYP and UGT inhibition to assess perpetrator drug-drug interaction potential	2
Pharmacokinetic properties of a truncated milk fat globule-EGF-like factor 8 in rats	2
Development and application of 3D cardiac tissues derived from human pluripotent stem cells	2
For hepatically cleared drugs, liver to blood KPUU at steady-state is always equal to FH , which exposes the deficiency of the present extended clearance concept equation	2
Imaging Mass Spectrometry (IMS) for drug discovery and development survey: Results on methods, applications and regulatory compliance	2
Transporter or membrane barriers effects on hepatic clearance (the extended clearance equation) models and the need for scaling for IVIVE	2
Microbiome impacts on drug metabolism	2
Reduced theophylline clearance due to hepatic congestion secondary to right heart failure - A population pharmacokinetic study	2
Establishment and characterization of an in vitro model for NTCP substrate and inhibition assessment	2
Difference in the lipid nanoparticle technology employed in three approved siRNA (Patisiran) and mRNA (COVID-19 vaccine) drugs	2
OATP1B-mediated hepatic uptake of low-molecular weight acid compounds: assessment of HIF prolyl-hydroxylase inhibitors (DUSTATS)	2
Involvement of multiple cytochrome P450 isoenzymes in drug interactions between ritonavir and direct oral anticoagulants	2
Population pharmacokinetic modeling of treosulfan and rationale for dose recommendation in children treated for conditioning prior to allogeneic hematopoietic stem cell transplantation	2
Elucidate the metabolism of lipidated serotonin and selected drugs by cytochrome P450 2U1 (CYP2U1) in nanodiscs	2
Ferulic acid prevents Diosbulbin B-induced liver injury by inhibiting covalent modifications on proteins	2
Synthetic molecule libraries for nucleic acid delivery: Design parameters in cationic/ionizable lipids and polymers	2
P-GP limits rodent oral absoprtion of protacs	2
Predicting drug metabolism and pharmacokinetics features of in-house compounds by a hybrid machine-learning model	1
Endosomal escape for intracellular delivery of RNA therapeutics: current and future strategies	1
A family study of compound variants of flavin-containing monooxygenase 3 (FMO3) in Japanese subjects found by urinary phenotyping for trimethylaminuria	1
LC-MS for identifying changes (or lack of it) in ADME across different cohorts	1
Establishment of human intestinal organoids derived from commercially available cryopreserved intestinal epithelium and evaluation for pharmacokinetic study	1
Quantitative proteomics identifies significant changes in the abundance and composition of hepatic drug metabolizing enzymes in heavy alcohol drinkers	1
Comparison of the transport kinetics of fexofenadine and its pH dependency among OATP1A2 genetic variants	1
Drug metabolism by the human gut microbiome	1
Designing novel RNA medicines for the brain	1
A live cell high content imaging assay for monitoring large molecule uptake into aproximate proximal tubule epithelial cells via megalin and cubilin	1
Population pharmacokinetics of blonanserin in Japanese adolescent and adult patients with schizophrenia	1
An improved TK-NOG mouse as a novel platform for humanized liver that overcomes limitations in both male and female animals	1
CYP46A1 inhibition and activation: an in vitro high throughput screening assay to assess possible drug interactions using FDA approved chemical library	1
Physiologically based pharmacokinetic (PBPK) model that describes enhanced FcRn-dependent distribution of monoclonal antibodies (mAbs) by pI-engineering in mice	1
Oxidative metabolism and pharmacokinetics of the EGFR inhibitor BIBX1382 in chimeric NOG-TKm30 mice transplanted with human hepatocytes	1
Characterization of LysoTracker Red uptake by in vitro model cells of the outer blood-retinal barrier: Implication of lysosomal trapping with cytoplasmic vacuolation and cytotoxicity	1
Bringing totality-of-evidence into PBPK predictions: fraction metabolised by aldehyde oxidase	1
Novel coc-based liver tissue chip for predictive pharmacokinetic and toxicology applications	1
Impacts of SNPs on adverse events and trough concentration of imatinib in patients with gastrointestinal stromal tumors	1
Assessment of the clinical pharmacokinetic interaction potential mediated So-Cheong-Ryong-Tang on a cocktail of anti-inflammatory and anti-biotic drugs, established by physiologically based pharmacoki	1
Validation of a modified in situ perfusion model for measuring drug intestinal excretion and evaluation of the drug-drug interactions in the intestine by I.V. administration	1
Downregulated expression of organic anion transporting polypeptide (Oatp) 2b1 in the small intestine of rats with acute kidney injury	1
Evaluation and prediction of oral drug absorption and bioequivalence with food-druginteraction	1
Metabolic pathways of aschantin in human liver preparations	1
Liver targeted therapy: What mist and DDI data mean for efficacy	1
Cross-species drug metabolism and impact of metabolic stability testing under anaerobic condition on predicting pharmacokinetics of keto-enol containing compound in humans	1
Impact of P-glycoprotein on intracellular drug concentration in peripheral blood mononuclear cells and K562 cells	1
Translational PK/PD of the targeted radioligand therapy pluvicto	1
Practical use of mechanistic modeling to discern real word complex drug interactions	1
Challenges associated with the biomarker-informed PBPK modeling of renal transporter-mediated drug interactions	1
Characterization of 14 pharmaceutical excipients in the CACO-2 permeability assay	1
Predicting muscarinic receptor occupancy in human bladder mucosa from urinary concentrations of antimuscarinic agents for overactive bladder	1
Using quantitative systems pharmacology (QSP) models to characterize the PK of novel drug modalities	0
Validation of LC-MS/MS method for the quantification of buprenorphine and its metabolites in rat’s blood, oral fluid, salivary gland and application the assay on pharmacokinetic study	0
NUDT15 is a key genetic factor for prediction of hematotoxicity in pediatric patients who received a standard low dosage regimen of 6-mercaptopurine	0
Opportunities and challenges in drug development for retinal diseases	0
UGT-mediated clearance IVIVE may be improved using relative activity factor approach	0
Simplified daptomycin dosing regimen for adult patients with methicillin-resistant Staphylococcus aureus infections based on population pharmacokinetic analysis	0

Cytochrome P450-dependent drug oxidation activities and their expression levels in liver microsomes of chimeric TK-NOG mice with humanized livers	0
Characterization of plasma vonoprazan and CYP3A activity using its endogenous marker and genetic variants in patients with digestive system disorders	0
A systematic study to evaluate the safety of ticagrelor combined with aspirin in the treatment of PCI patients in Chinese population: A single nucleotide polymorphisms study	0
Investigating protein-mediated uptake drug-drug interactions using F-methotrexate as a substrate for OATP1B1 transporter	0
Exposure-response analysis of the efficacy and safety of esaxerenone, a novel nonsteroidal mineralocorticoid receptor blocker, in hypertensive patients with or without diabetic kidney disease	0
Drug metabolism: A half-century plus of progress, continued needs, and new opportunities	0
Approach to de-risk structural alerts in compound progression	0
In silico approach shows good predictability for free fraction in plasma and volume of distribution in human for drugs subjected to lysosomal trapping	0
Investigating cross-species differences of MDR1-mediated drug transport	0
Unveiling the intra-tumor fate of trastuzumab deruxtecan in a xenograft model to support its mechanism of action	0
Diclofenac potentiates the antitumor effect of cisplatin in a xenograft mouse model transplanted with cisplatin-resistant cells without enhancing cisplatin-induced nephrotoxicity	0
In vitro evaluation of PROTAC® degrader ARV-766 for cytochrome P450- and transporter-mediated drug-drug interaction	0
Effects of steric hindrance and electron density of ester prodrugs on controlling the metabolic activation by human carboxylesterase	0
14C-radiolabeled human ADME: a review of clinical microtracer mass balance data	0
Animal species differences in the pyridoxine transport function of SLC19A3: Absence of Slc19a3-mediated pyridoxine uptake in the rat small intestine	0
Is CYP3A4 induction a good indicator for CYP2CS in cryopreserved human hepatocytes?	0
Optimization of methods for reducing turnaround time and compound consumptionwith echo liquid handling and automation enabling high capacity analysis for ADME screening	0
Mechanistic pharmacokinetics & pharmacodynamics of GaINAc-siRNA	0
Strategies for DDI risk assessment between novel oncology agents and combination generic standard of care (SOC) agents	0
A UPLC-MS/MS method reveals the pharmacokinetics and metabolism characteristics of kaempferol in rats under hypoxia	0
Novel approach to determine plasma protein binding for labile compounds using equilibrium dialysis	0
Transcript abundance of hepatic drug-metabolizing enzymes in two dog breeds compared with 14 species including humans	0
Encequidar is a gut-restricted P-GP specific inhibitor that boosts oral bioavailability and inhibits intestinal secretion in rats and dogs.	0
Construction of a fused grid-based CYP2C19-Template system and the application	0
CNS penetration of methotrexate and its metabolite 7-hydroxymethotrexate in mice bearing orthotopic Group 3 medulloblastoma tumors and model-based simulations for children	0
Development of plasma stability assay for oligonucleotides	0
Can prostaglandins be used as biomarkers for atypical antipsychotic mediated immune system dyregulation in zebra fish?	0
Can LS180 cells predict metabolism and drug-drug interaction potential of UGT2B17 substrates?	0
Quantification of fluticasone propionate in human plasma by LC–MS/MS and its application in the pharmacokinetic study of nasal spray at clinical doses	0
Functional role of serine 318 of the proton-coupled folate transporter in methotrexate transport	0
Successful optimization of pharmacokinetics and pharmacodynamics of oral cyclic peptide PCSK9 inhibitors	0
In vitro characterization of taurine transport using the human brain microvascular endothelial cell line as a human blood-brain barrier model	0
Characteristics of membrane transport, metabolism, and target protein binding of cyclic depsipeptide destruxin E in HeLa cells	0
A novel method for predicting the unbound valproic acid concentration	0
An overview of CDE technical guideline for nonclinical study of ADCS: importance and strategy of studying release of payload-containing components from ADC and their further metabolism	0
Probe drug T-1032 N-oxygenation mediated by cytochrome P450 3A5 in human hepatocytes in vitro and in humanized-liver mice in vivo	0
Extrapolation of physiologically based pharmacokinetic model for tacrolimus from renal to liver transplant patients	0
Functional characteristics of equilibrative nucleoside transporter 2 (ENT2/SLC29A2) for the transport of urate as a newly identified substrate	0
The mass balance, recovery, absorption, metabolism, and excretion of [14C]-orvepitant in healthy male subjects after oral dosing: metabolite characterisation	0
High-throughput assessment for drug protein binding using magnetized silica beads method in human liver microsomes	0
Comprehensive in vitro evaluation of the inhibitory effects of relatively high molecular weight peptides on drug-drug interaction-associated four liver transporters and its association with physicoche	0
A successful preclinical toxicology package	0
Effect of substrate concentration on reactive metabolite assessment in drug discovery research	0
Ilexsaponin A1: In vitro metabolites identification and evaluation of inhibitory drug-drug interactions	0
Pharmacokinetics and safety of rilpivirine in healthy Japanese subjects and exploration of ethnic sensitivity of rilpivirine pharmacokinetics with physiologically based pharmacokinetic model approach	0
A procedure for method development and protein binding ratio as the indicator of sensitivity with anticancer agents on MALDI mass spectrometry imaging	0
Understanding mechanisms of negative food effect for voclosporin using physiologically based pharmacokinetic modeling	0
Clinical DDI trial design and impact on product labels	0
DMPK perspective on quantitative model analysis for chimeric antigen receptor cell therapy: Advances and challenges	0
Converting suspension-type human primary hepatocytes to be plateable-type for use as an in vitro pharmacokinetics model	0
In vitro liver models for toxicological research	0
Assessment of covalent binding body burden in Hmrel human hepatocyte co-culture model for metabollically low turnover compounds	0
Determination of metabolic pathways of phosphatidylcholine and lysophosphatidylcholine using a stable isotope tracer in hepatocarcinoma cell lines	0
Pharmacokinetics of genistein distribution in blood and retinas of diabetic and non-diabetic rats	0
Pharmacokinetics of perfluoroocanoic acid and perfluorohexane sulfonic acid in various rat models	0
Investigation of the learning process of diverse compound structures by chemical language models toward toxicity prediction	0
Inhibiting uptake activity of organic anion transporter 2 by bile acids	0
Transporter activity characterization in a novel human hepatic cell-based tri-culture system	0
Phenolsulfonphthalein as a surrogate substrate to assess altered function of the prostaglandin transporter SLCO2A1	0
Physiologically based pharmacokinetic model analysis of the inhibitory effect of vonoprazan on the metabolic activation of proguanil	0
Exploring the potential of machine learning approach in predicting clinical CYP3A induction-mediated drug-drug interaction	0
Delivery of small interfering RNAs by nanovesicles for cancer therapy	0
Identification and characterization of novel metabolites of F2-isoprostanes	0
In vitro inhibitory effects of components from Salvia miltiorrhiza on catalytic activity of three human Arachidonic acid ω-hydroxylases	0
Hepatocyte formation, reactivity, and stability differences of acyl glucuronide and acyl coenzyme a conjugates	0
Assessing victim drug-drug interaction – Reaction phenotyping of CYP and non-CYP	0
Future direction of animal alternative/microphysiological systems in drug discovery and development	0
Adeno-associated virus-mediated knockdown demonstrates the major role of hepatic Bcrp in the overall disposition of the active metabolite of the tyrosine kinase inhibitor regorafenib in mice	0
Experiences in industry predicting hepatic clearance: Successes, disconnects, failures, and room for improvement	0
Development of a fluorescent-labeled trapping reagent to evaluate the risk posed by acyl-CoA conjugates	0
What is new in LC-MS proteomics: Techniques and applications in IVIVE and precision medicine	0
Approaches to predict human PK profiles for compounds undergoing transporter mediated clearance in early drug development: From dedrick plot to PBPK modeling	0
Advanced in vitro evaluation of drug-induced kidney injury using microphysiological systems in drug discovery and development	0
In vitro evaluation of metabolism- and transporter-based drug interactions with sunscreen active ingredients	0
Improving in vitro clearance assay performance and prediction accuracy with advanced human hepatocyte models for highly stable RO5 and BRO5 compounds	0
In vitro hydrolysis of areca nut xenobiotics in human liver	0
Smart compound library based on machine learning, sensing technology, and programmable logic control	0
Identification and characterization of erlotinib as a potent mechanism-based inactivator of human aldehyde oxidase	0
Biotransformation of protein degraders bavdegalutamide and XL01126 in permeabilized cryopreserved human hepatocytes	0
Associations of HLA and drug-metabolizing enzyme genes in co-trimoxazole-induced severe cutaneous adverse reactions	0
Novel metabolomics approach to identify biomarkers of organic anion renal transporters	0
Inhibition of cytochrome P450 3A4 enzyme activity by alkaloid psilocin from magic mushrooms: potential for drug interactions	0
The inhibitory effects of major cannabinoids and their metabolites on R- and S-oxazepam metabolism	0
Bioavailability of tetracyclines is substantially increased by administration of cyclosporine A, a non-specific efflux-pump blocker	0
Clotrimazole is a potent and selective UGT2B4 chemical inhibitor	0
High hepatic and plasma exposures of atorvastatin in subjects harboring impaired cytochrome P450 3A4∗16 modeled after virtual administrations and possibly associated with statin intolerance found in t	0
Development of a HRMS-MS method for measuring plasma 4Β-hydroxycholesterol, an endogenous biomarker of CYP3A activity, in monkeys treated with CYP3A modulators	0
Establishment of MDR1-knockout human enteroids for pharmaceutical application	0
Prevention of irinotecan-induced intestinal toxicity by locally bioavailable herbal components via maintaining gut oxidative stress homeostasis	0
Genetic variation present in the CYP3A4 gene in Ni-Vanuatu and Kenyan populations in malaria endemicity	0
Preferential meropenem absorption activated by 1α,25-dihydroxyvitamin D3 and shared with foscarnet, a phosphate transporter substrate, in the rat ileum	0
Absorption, metabolism, and excretion of inavolisib (GDC-0077), a PI3KA inhibitor in humans	0
WITHDRAWN: Drugs that induce and inhibit cytochrome P450. A study with real-world evidence	0
Evaluation of a cost-effective in vitro human model for predicting intrinsic hepatocyte clearance of slowly metabolized compounds	0
Development of intestinal organoids and microphysiological systems and their application to drug discovery	0